Durin Technologies announced funding of $3.5 million led by Breakthrough Diagnostics, LLC. The funding will accelerate Durin’s next key stages of anticipated growth, involving commercialization of its novel diagnostic tests focusing on Alzheimer’s and Parkinson’s diseases and development of its next generation of diagnostic tests that detect other diseases and disorders at their earliest stages.
Read also – [Funding alert] X-energy Finalizes $235 Million Series C Financing
The funding will accelerate Durin’s next key stages of anticipated growth, involving commercialization of its novel diagnostic tests focusing on Alzheimer’s and Parkinson’s diseases and development of its next generation of diagnostic tests that detect other diseases and disorders at their earliest stages.
Read also – AppsFlyer Acquires oolo to Transform AI-driven Decision-Making For Marketing and Growth
Durin Technologies CEO Mert Sahin, Ph.D., said, “With this latest funding, we are poised to bring our tests into the market and move closer to satisfying the demands of physicians, patients and their loved ones with fast, easy-to-understand and reliable diagnosis of life altering diseases.”
Read also – [Funding alert] DUST Identity Secures $40 Mn Series B Funding
About Durin Technologies, Inc.
Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Its rapid-result, high-accuracy DuritectTM diagnostic tests make early detection and monitoring of disease progression possible – in a decade or more prior to symptoms in some cases.
Read also – The Predictive Index Acquires Charma, The Performance Management Platform
Durin’s first two tests – for Alzheimer’s and Parkinson’s – will come to market in 2024, followed by tests for other diseases. The company’s groundbreaking science creates a scalable platform for diagnostic tests that will extend beyond the multi-billion-dollar neurodegenerative diagnostics market into the much larger, broader disease diagnostic market.
Read also – [Funding alert] Asato.ai Raises $7.5 Mn Seed Funding Co-led by Intel Capital and Lip-Bu Tan
